These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 39419345)

  • 1. ASPSCR1::TFE3-mediated upregulation of insulin receptor substrate 2 (IRS-2) activates PI3K/AKT signaling and promotes malignant phenotype.
    Ishiguro N; Nakagawa M
    Int J Biochem Cell Biol; 2024 Nov; 176():106676. PubMed ID: 39419345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1-TFE3 fusion oncoprotein.
    Kobos R; Nagai M; Tsuda M; Merl MY; Saito T; Laé M; Mo Q; Olshen A; Lianoglou S; Leslie C; Ostrovnaya I; Antczak C; Djaballah H; Ladanyi M
    J Pathol; 2013 Apr; 229(5):743-754. PubMed ID: 23288701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions.
    Martignoni G; Gobbo S; Camparo P; Brunelli M; Munari E; Segala D; Pea M; Bonetti F; Illei PB; Netto GJ; Ladanyi M; Chilosi M; Argani P
    Mod Pathol; 2011 Oct; 24(10):1313-9. PubMed ID: 21602817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ASPSCR1::TFE3 Drives Alveolar Soft Part Sarcoma by Inducing Targetable Transcriptional Programs.
    Sicinska E; Kola VSR; Kerfoot JA; Taddei ML; Al-Ibraheemi A; Hsieh YH; Church AJ; Landesman-Bollag E; Landesman Y; Hemming ML
    Cancer Res; 2024 Jul; 84(14):2247-2264. PubMed ID: 38657118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases.
    Hodge JC; Pearce KE; Wang X; Wiktor AE; Oliveira AM; Greipp PT
    Mod Pathol; 2014 Jan; 27(1):113-27. PubMed ID: 23828314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.
    Damayanti NP; Budka JA; Khella HWZ; Ferris MW; Ku SY; Kauffman E; Wood AC; Ahmed K; Chintala VN; Adelaiye-Ogala R; Elbanna M; Orillion A; Chintala S; Kao C; Linehan WM; Yousef GM; Hollenhorst PC; Pili R
    Clin Cancer Res; 2018 Dec; 24(23):5977-5989. PubMed ID: 30061365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Technique for differentiating alveolar soft part sarcoma from other tumors in paraffin-embedded tissue: comparison of immunohistochemistry for TFE3 and CD147 and of reverse transcription polymerase chain reaction for ASPSCR1-TFE3 fusion transcript.
    Tsuji K; Ishikawa Y; Imamura T
    Hum Pathol; 2012 Mar; 43(3):356-63. PubMed ID: 21835426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ASPSCR1-TFE3 fusion in a case of Xp11 translocation PEComa of the liver: are ASPSCR1-TFE3 fusion-bearing tumours Xp11 translocation PEComa or alveolar soft part sarcoma?
    Chai J; Ma J; Liu Y; Zhao D; Yin Z; Wang Z; Fan L
    Pathology; 2023 Apr; 55(3):416-419. PubMed ID: 36104270
    [No Abstract]   [Full Text] [Related]  

  • 9. ASPSCR1-TFE3 reprograms transcription by organizing enhancer loops around hexameric VCP/p97.
    Pozner A; Li L; Verma SP; Wang S; Barrott JJ; Nelson ML; Yu JSE; Negri GL; Colborne S; Hughes CS; Zhu JF; Lambert SL; Carroll LS; Smith-Fry K; Stewart MG; Kannan S; Jensen B; John CM; Sikdar S; Liu H; Dang NH; Bourdage J; Li J; Vahrenkamp JM; Mortenson KL; Groundland JS; Wustrack R; Senger DL; Zemp FJ; Mahoney DJ; Gertz J; Zhang X; Lazar AJ; Hirst M; Morin GB; Nielsen TO; Shen PS; Jones KB
    Nat Commun; 2024 Feb; 15(1):1165. PubMed ID: 38326311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ASPSCR1::TFE3 orchestrates the angiogenic program of alveolar soft part sarcoma.
    Tanaka M; Chuaychob S; Homme M; Yamazaki Y; Lyu R; Yamashita K; Ae K; Matsumoto S; Kumegawa K; Maruyama R; Qu W; Miyagi Y; Yokokawa R; Nakamura T
    Nat Commun; 2023 Apr; 14(1):1957. PubMed ID: 37029109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PEComa with ASPSCR1::TFE3 fusion: expanding the molecular genetic spectrum of TFE3-rearranged PEComa with an emphasis on overlap with alveolar soft part sarcoma.
    Zhao M; Huang Y; Yin X; Xu J; Sun Y; Wang J
    Histopathology; 2024 Feb; 84(3):482-491. PubMed ID: 37936565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alveolar Soft Part Sarcoma.
    Jaber OI; Kirby PA
    Arch Pathol Lab Med; 2015 Nov; 139(11):1459-62. PubMed ID: 26516944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of the ASPSCR1-TFE3 gene fusion in paraffin-embedded alveolar soft part sarcomas.
    Aulmann S; Longerich T; Schirmacher P; Mechtersheimer G; Penzel R
    Histopathology; 2007 Jun; 50(7):881-6. PubMed ID: 17543078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage.
    Ellis CL; Eble JN; Subhawong AP; Martignoni G; Zhong M; Ladanyi M; Epstein JI; Netto GJ; Argani P
    Mod Pathol; 2014 Jun; 27(6):875-86. PubMed ID: 24309327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PEComa-like Neoplasms Characterized by ASPSCR1-TFE3 Fusion: Another Face of TFE3-related Mesenchymal Neoplasia.
    Argani P; Wobker SE; Gross JM; Matoso A; Fletcher CDM; Antonescu CR
    Am J Surg Pathol; 2022 Aug; 46(8):1153-1159. PubMed ID: 35848761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TFE3/PI3K/Akt/mTOR Axis in Renal Cell Carcinoma Affects Tumor Microenvironment.
    Hwang C; Kang YK; Kim JY; Shin SH; Park JY; Song JS; Kim SY; Jung SJ; Lee JH; Na JY; Shin DH; Kim JY; Park SW; Lee HJ
    Am J Pathol; 2024 Jul; 194(7):1306-1316. PubMed ID: 38588851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients with ASPSCR1-TFE3 fusion achieve better response to ICI based combination therapy among TFE3-rearranged renal cell carcinoma.
    Zhao J; Tang Y; Hu X; Yin X; Chen Y; Chen J; Liu H; Liu H; Liang J; Zhang X; Zhao J; Zhu S; Ni Y; Wang Z; Dai J; Wang Z; Zhang Y; Yao J; Chen N; Shen P; Liu ZH; Zeng H; Sun GX
    Mol Cancer; 2024 Jun; 23(1):132. PubMed ID: 38926757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.
    Reis H; Hager T; Wohlschlaeger J; Bauer S; Katenkamp K; Katenkamp D; Baba HA
    Hum Pathol; 2013 Oct; 44(10):2266-74. PubMed ID: 23871289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents.
    Argani P; Antonescu CR; Illei PB; Lui MY; Timmons CF; Newbury R; Reuter VE; Garvin AJ; Perez-Atayde AR; Fletcher JA; Beckwith JB; Bridge JA; Ladanyi M
    Am J Pathol; 2001 Jul; 159(1):179-92. PubMed ID: 11438465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Alveolar Soft Part Sarcoma-The Angiogenic Mechanism Regulated by a Fusion Gene Product].
    Nakamura T; Tanaka M
    Gan To Kagaku Ryoho; 2024 Jun; 51(6):585-590. PubMed ID: 39009511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.